News|Articles|November 17, 2026

FDA Adds Head-to-Head MAPLE-HCM Data to Aficamten Label in oHCM

Fact checked by: Ashley Gallagher, MA
Listen
0:00 / 0:00

Key Takeaways

  • FDA cleared an sNDA adding MAPLE-HCM comparative data to aficamten’s oHCM label, while the indication remains improving functional capacity and symptoms in symptomatic obstructive HCM.
  • MAPLE-HCM randomized 175 adults to aficamten 5–20 mg or metoprolol 50–200 mg daily for 24 weeks using a double-blind, double-dummy design.
SHOW MORE

The updated label now includes phase 3 data comparing aficamten monotherapy with metoprolol in adults with symptomatic obstructive HCM.

Prescribing information for aficamten (Myqorzo; Cytokinetics), a cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), now includes phase 3 data showing greater improvement in exercise capacity than with the beta-blocker metoprolol, according to a press release.1

“People living with HCM deserve treatment decisions grounded in rigorous evidence. For decades, beta-blockers have been a cornerstone of treatment for oHCM in the absence of rigorously conducted clinical trials demonstrating their utility in this condition,” Robert I. Blum, president and chief executive officer, Cytokinetics, said in a statement. “In MAPLE-HCM, Myqorzo demonstrated significantly greater improvements in exercise capacity, symptom burden, and cardiac biomarkers compared to metoprolol. Myqorzo is now the only cardiac myosin inhibitor with evidence comparing its effectiveness to a beta-blocker for the treatment of oHCM in its US label, providing cardiologists and patients important information to inform treatment decisions.”

The FDA approved a supplemental new drug application (sNDA) adding results from MAPLE-HCM (NCT05767346), which compared aficamten and metoprolol, each as monotherapy, in adults with symptomatic oHCM. The indication is unchanged: aficamten remains approved to improve functional capacity and symptoms in this population. With the update, Cytokinetics said aficamten is the only cardiac myosin inhibitor whose US label includes evidence comparing its effectiveness with a beta-blocker.

Aficamten Improved Peak Oxygen Uptake vs Metoprolol

MAPLE-HCM was a multicenter, randomized, double-blind, double-dummy trial that assigned 175 adults with symptomatic oHCM 1:1 to aficamten 5 mg to 20 mg daily (n = 88) or metoprolol 50 mg to 200 mg daily (n = 87) for 24 weeks.2 Full results were published in 2025 in The New England Journal of Medicine.

At week 24, peak oxygen uptake (pVO2), the primary end point, increased by 1.1 mL/kg/min (95% CI, 0.5-1.7) with aficamten and decreased by 1.2 mL/kg/min (95% CI, –1.7 to –0.8) with metoprolol. Aficamten also significantly improved 5 of 6 secondary end points vs metoprolol: New York Heart Association functional class, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, N-terminal pro–B-type natriuretic peptide, left ventricular outflow tract gradient after Valsalva maneuver, and left atrial volume index. The sixth, left ventricular mass index, did not differ significantly between groups. The effect on pVO2 was consistent across all prespecified subgroups, including patients who were newly diagnosed or treatment naive.1

Hypertension More Common With Aficamten; Boxed Warning Remains

Overall adverse event rates were similar between the 2 arms. Hypertension was the most common adverse event, occurring more often with aficamten than with metoprolol (15% vs 3%), whereas dizziness was the most common one, occurring more often with metoprolol.

Aficamten's label continues to carry a boxed warning for the risk of heart failure, as the drug reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Initiation is not recommended in patients with an LVEF below 55%, and dosing should be interrupted if LVEF falls below 40% or if patients experience heart failure symptoms or worsening clinical status due to systolic dysfunction. The drug is available only through a Risk Evaluation and Mitigation Strategy program and is contraindicated with rifampin.

Evidence Gap for Beta-Blockers as First-Line Therapy

Beta-blockers have been the initial treatment for symptomatic oHCM despite limited evidence of their efficacy, the MAPLE-HCM investigators noted, and whether aficamten monotherapy offered greater benefit than beta-blocker monotherapy had been unknown before the trial.2

The FDA first approved aficamten in December 2025 based on SEQUOIA-HCM, a placebo-controlled phase 3 trial in patients receiving background therapy.1 Following results from the phase 3 ACACIA-HCM trial in nonobstructive HCM, Cytokinetics plans to submit an sNDA for that population in the fourth quarter of 2026.

References

  1. Cytokinetics announces prescribing information for MYQORZO (aficamten) expanded to include data from phase 3 MAPLE-HCM. News release. Cytokinetics. November 16, 2026. Accessed November 17, 2026. https://ir.cytokinetics.com/press-releases/press-release-details/2026/Cytokinetics-Announces-Prescribing-Information-for-MYQORZO-aficamten-Expanded-to-Include-Data-from-Phase-3-MAPLE-HCM/default.aspx
  2. Garcia-Pavia P, Maron MS, Masri A, et al. Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy. N Engl J Med. 2025;393(10):949-960. doi:10.1056/NEJMoa2504654

Related to this article